Curis Inc. (NASDAQ: CRIS) Stock Declined -5.72% Last Week – That’s Proof That Its Volatility Isn’t Going Anywhere


Curis Inc. (NASDAQ:CRIS) does about 819.06K shares in volume on a normal day but saw 293507 shares change hands in Friday trading. The company now has a market cap of 65.62M USD. Its current market price is $0.68, marking an increase of 3.57% compared to the previous close of $0.66. The 52 week high reached by this stock is $3.52 whilst the lowest price level in 52 weeks is $0.47. The script in recent trading has seen the stock touch a high of $0.694 and a low of $0.65.

Do You Know The Best Place To Find Gains In Volatile Markets?

In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.

Click here for full details and to join for free.


Curis Inc. (CRIS) has a 20-day trading average at $0.7395 and the current price is -80.53% off the 52-week high compared with 45.64% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.6641 and its 200-day simple moving average is $0.8541. If we look at the stock’s price movements over the week, volatility stands at 5.87%, which increases to 6.42% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 44.34 to suggest the stock is neutral.

5 analysts observing the Curis Inc. (CRIS) stock have set the 12-month price targets for the company’s shares at between $3.00 and $10.00. The consensus objective for the share price is $6.75, suggesting that the stock has a potential upside of 89.93% over the period. The median price target is 90.29% away from the current levels at $7.00.

FactSet Research has provided data showing that 5 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 4 analysts have rated it as a buy and 1 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Moderate Buy the stock.

B. Riley Securities initiated its price target at $19.

The current price level is -7.53%, 2.85%, and -20.02% away from its SMA20, SMA50, and SMA200 respectively, with the CRIS price moving below the 50-day SMA on February 17. Curis Inc. (CRIS) stock is down -5.72% over the week and -4.93% over the past month. Its price is 24.45% year-to-date and -80.66% over the past year.

The stock last released its quarterly earnings report for quarter ended 9/29/2022, with the company’s earnings per share (EPS) of -$0.14 above consensus estimates by $0.03. The company’s next earnings report is expected on 05/04/2023, with forecasts estimating quarterly EPS at -$0.13 and -$0.62 for whole year. CRIS’s earnings per share are forecast to shrink by -24.00% this year and 30.60% over next year. Expected sales for next quarter are $2.62 million, which analysts say will come at $10.47 million for the current fiscal year and next year at $11.23 million. In addition, estimates put the company’s current quarterly revenue at an average of $3.18 million.

To reach the target analysts have set, the stock logically needs to grow 89.93 percent from here.

Outstanding shares total 93.79M with insiders holding 5.94% of the shares and institutional holders owning 41.21% of the company’s common stock. The company has a return on investment of -45.40% and return on equity of -82.90%. The beta has a value of 2.87. Price to book ratio is 1.16 and price to sales ratio is 6.31.

Fidelity Extended Market Index Fu cut their holdings by -0.41% in the company over the course of the most recent quarter. It now holds a 0.44% position in Curis Inc. thanks to 0.42 million shares amounting to $0.31 million.


Please enter your comment!
Please enter your name here